

| NDC | Product Description | Pack Size | WAC | Launch Date | Marketing and Pricing Plans | Estimated Patient Volume | Breakthrough Therapy Designation | Priority Review | Date and Price of Acquisition |
|---------------|----------------------------|-----------|-------------|-------------|--|--|----------------------------------|-----------------|--------------------------------------|
| 70710-1030-07 | Lenalidomide 2.5mg Capsule | 28 | \$20,157.36 | 03/06/2023 | Zydus does not market or promote its generic products to prescribers or patients. Zydus sells its products to retailers and wholesalers. Zydus prices its products based on the current market conditions. | As Zydus manufactures generic products, we do not estimate the number of patients that may be prescribed our products. We manufacture volume based on an estimated market share along with IQVIA EUTRx data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. | No | No | This product was developed by Zydus. |
| 70710-1034-08 | Lenalidomide 20mg Capsule | 21 | \$15,118.04 | 03/06/2023 | Zydus does not market or promote its generic products to prescribers or patients. Zydus sells its products to retailers and wholesalers. Zydus prices its products based on the current market conditions. | As Zydus manufactures generic products, we do not estimate the number of patients that may be prescribed our products. We manufacture volume based on an estimated market share along with IQVIA EUTRx data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. | No | No | This product was developed by Zydus. |